ProQR Therapeutics ( NASDAQ:PRQR – Get Rating ) was upgraded by investment analysts at StockNews.com from a 'sell' rating to a 'hold' rating in a research note issued on Tuesday. Other analysts also recently issued reports about the company. Raymond James lifted their target price on ProQR Therapeutics from $2.00 to $5.00 and gave the stock an 'outperform' rating in a research report on Friday, December 23rd. Cantor Fitzgerald upgraded ProQR Therapeutics from a 'neutral' rating to an 'overweight' rating and set a $5.

https://www.dailypolitical.com/2023/03/07/proqr-therapeutics-nasdaqprqr-upgraded-at-stocknews-com.html

#dailypolitical